It has been proposed that simultaneous targeting of MAPK/ERK and PI3K/AKT signaling pathways may be effective in treatment of different types of leukemia without knowledge of the mutation responsible for aberrant activations of these pathways [13]. The gene discussed is MAPK1; the disease is leukemia.